Literature DB >> 27317514

The incidence of herpes zoster in cutaneous lupus erythematosus (CLE), dermatomyositis (DM), pemphigus vulgaris (PV), and bullous pemphigoid (BP).

Elizabeth S Robinson1, Aimee S Payne2, Lisa Pappas-Taffer3, Rui Feng4, Victoria P Werth5.   

Abstract

BACKGROUND: Herpes zoster is a common condition that causes significant morbidity.
OBJECTIVE: This study determined the incidence of zoster in patients with cutaneous lupus erythematosus (CLE), dermatomyositis (DM), pemphigus vulgaris (PV), and bullous pemphigoid (BP).
METHODS: In this retrospective cohort study the electronic medical records of 186 patients with CLE, 103 with DM, 83 with PV, 44 with BP, and 152 healthy control patients were reviewed to confirm positive diagnoses of zoster.
RESULTS: The incidence of zoster per 1000 person-years was 29.4 in CLE, 55.4 in DM, 18.6 in PV, 10.2 in BP, and 3.9 in healthy control subjects. The mean age (SD) in years was 46.1 (14.9) for CLE, 52.2 (14.5) for DM, 51.8 (13.5) for PV, 71.44 (11.8) for BP, and 48.2 (18.2) for healthy control subjects. The incidence of zoster was significantly higher in the CLE (P = .0177) and DM (P = .0070) groups than the healthy control subjects, all of whom were of a similar mean age. LIMITATIONS: The limitations of this study are the sample size, referral bias, and retrospective nature.
CONCLUSION: The incidence of zoster in patients with CLE and, particularly, DM was significantly higher than that of the healthy control subjects. Published by Elsevier Inc.

Entities:  

Keywords:  autoimmune disease; bullous pemphigoid; cutaneous lupus erythematosus; dermatomyositis; herpes zoster; pemphigus vulgaris; shingles

Mesh:

Year:  2016        PMID: 27317514     DOI: 10.1016/j.jaad.2016.02.1153

Source DB:  PubMed          Journal:  J Am Acad Dermatol        ISSN: 0190-9622            Impact factor:   11.527


  5 in total

Review 1.  Autoimmune Subepidermal Bullous Diseases of the Skin and Mucosae: Clinical Features, Diagnosis, and Management.

Authors:  Kyle T Amber; Dedee F Murrell; Enno Schmidt; Pascal Joly; Luca Borradori
Journal:  Clin Rev Allergy Immunol       Date:  2018-02       Impact factor: 8.667

2.  Mortality risk after herpes zoster infection in end-stage renal disease patients.

Authors:  John H Ahn; Jennifer L Waller; Stephanie L Baer; Rhonda E Colombo; Mufaddal F Kheda; N Stanley Nahman; Jake E Turrentine
Journal:  Clin Kidney J       Date:  2018-07-17

3.  Clinical Patterns, Survival, Comorbidities, and Treatment Regimens in 149 Patients With Pemphigus in Tuscany (Italy): A 12-Year Hospital-Based Study.

Authors:  Lavinia Quintarelli; Alessio Coi; Roberto Maglie; Alberto Corrà; Elena Biancamaria Mariotti; Cristina Aimo; Valentina Ruffo di Calabria; Alice Verdelli; Beatrice Bianchi; Elena Del Bianco; Emiliano Antiga; Marzia Caproni
Journal:  Front Immunol       Date:  2022-07-08       Impact factor: 8.786

4.  Herpes zoster infection after topical steroid use in the setting of tumid lupus erythematosus.

Authors:  Rachel Powell; Grace Hile; Lori Lowe; J Michelle Kahlenberg
Journal:  JAAD Case Rep       Date:  2017-12-20

5.  Incidence and prevalence of vaccine preventable infections in adult patients with autoimmune inflammatory rheumatic diseases (AIIRD): a systemic literature review informing the 2019 update of the EULAR recommendations for vaccination in adult patients with AIIRD.

Authors:  Victoria Furer; Christien Rondaan; Marloes Heijstek; Sander van Assen; Marc Bijl; Nancy Agmon-Levin; Ferdinand C Breedveld; Raffaele D'Amelio; Maxime Dougados; Meliha Crnkic Kapetanovic; Jacob M van Laar; Annette Ladefoged de Thurah; Robert Landewé; Anna Molto; Ulf Müller-Ladner; Karen Schreiber; Leo Smolar; Jim Walker; Klaus Warnatz; Nico M Wulffraat; Ori Elkayam
Journal:  RMD Open       Date:  2019-09-19
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.